High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3–4: results of a 12-week double-blind, randomized, controlled study

Per-Anton Westerberg1,2, Gunnar Sterner3, Östen Ljunggren1, Elin Isaksson3, Fjölnir Elvarson1, Hamid Dezfoolian4 and Torbjörn Linde1

1Uppsala University, Medical Sciences, Uppsala, Sweden, 2County Hospital, Jönköping, Sweden, 3Skåne University Hospital, Malmö, Sweden and 4Sahlgrenska University Hospital, Gothenburg, Sweden

Correspondence and offprint requests to: Torbjörn Linde; E-mail: torbjorn.linde@medsci.uu.se

ABSTRACT

Background. Calcidiol insufficiency may accelerate the development of secondary hyperparathyroidism (SHPT). We tested the effect of a substantial increase in calcidiol on mineral metabolism in patients with chronic kidney disease (CKD).

Methods. Ninety-five patients with CKD Stages 3–4, parathyroid hormone (PTH) above 6.8 pmol/L and calcidiol below 75 nmol/L were randomized to receive either cholecalciferol 8000 IU/day or placebo for 12 weeks. The primary endpoint was difference in the mean change in iPTH after 12 weeks. The proportion of participants having a 30% reduction in PTH and the effect on hand grip strength, fatigue and different biochemical variables were also investigated.

Results. Baseline calcidiol was 57.5 ± 22 and 56.8 ± 22 nmol/L in the cholecalciferol and placebo groups, respectively. The corresponding concentrations of PTH were 10.9 ± 5 and 13.1 ± 9 pmol/L. Calcidiol increased to 162 ± 49 nmol/L in patients receiving cholecalciferol, and PTH levels remained constant at 10.5 ± 5 pmol/L. In the placebo group, calcidiol remained stable and PTH increased to 15.2 ± 11 pmol/L. The mean change in PTH differed significantly between the two groups (P < 0.01). The proportion of subjects reaching a 30% decrease in PTH did not differ. No effect on grip strength, fatigue, phosphate or fibroblast growth factor 23 was observed. Cholecalciferol treatment resulted in stable calcium concentrations and a substantial increase in calcitriol.

Conclusion. Treatment with high daily doses of cholecalciferol in patients with CKD Stages 3–4 halts the progression of SHPT and does not cause hypercalcaemia or other side effects.

Keywords: cholecalciferol, chronic renal failure, FGF23, secondary hyperparathyroidism, vitamin D

INTRODUCTION

A plasma concentration of calcidiol [25-hydroxy vitamin D (25(OH)D)] below 75 nmol/L is associated with an increase in parathyroid hormone (PTH) in healthy subjects [1–3]. Chronic kidney disease (CKD) patients are prone to develop 25(OH)D deficiency and clinical guidelines recommend replenishment with nutritional vitamin D, as ergo- or cholecalciferol, to attain a 25(OH)D plasma concentration above 75 nmol/L [4, 5]. Furthermore, low 25(OH)D levels have been suggested to be associated with impaired muscle and bone function [2, 6]. As various tissues express the ability to internalize, metabolize and elicit responses to vitamin D, it has been hypothesized that 25(OH)D may have multiple beneficial pleiotropic effects apart from being a substrate for the formation of calcitriol [1,25(dihydroxy) vitamin D [1,25(OH)2 vitamin D]] [6, 7].

The primary aim of this study was to determine if treatment with high-dose cholecalciferol (8000 IU/day as oral drops) for 12 weeks in CKD Stages 3–4 patients with secondary hyperparathyroidism (SHPT) resulted in differences in change in PTH levels as compared with placebo. Secondary outcomes were differences in mean change in PTH after 6 weeks and evaluation of fatigue, hand grip strength and different biochemical variables.
Subjects

Consecutive patients from three outpatient renal clinics in Sweden (Uppsala, Malmö and Gothenburg) with CKD Stages 3 and 4, PTH above 6.8 pmol/L, and 25(OH)D below 75 nmol/L were invited to participate in the study. All subjects had to be 18–85 years of age, have an estimated glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease formula between 15 and 59 mL/min/1.73 m² and sign informed consent. Exclusion criteria were presumed need for renal replacement therapy within 6 months, ionized calcium above 1.30 mmol/L, ongoing acute or chronic systemic inflammatory disease, pregnancy, renal transplant, known disease with significant effect on mineral metabolism such as granulomatous diseases, malabsorption, primary hyperparathyroidism or active malignancy. Ongoing treatment with paricalcitol, calcimimetics or a daily intake of pharmaceutical ergo- or cholecalciferol in a dose above 400 IU were exclusions, whereas a stable low per oral dose of 1-alfacalcidiol was accepted if the dose remained unchanged during the study.

Protocol

This was a 12-week double-blind, randomized, placebo-controlled clinical trial (EudraCT 2011-002586-38). Eligible subjects were randomly assigned to receive 8000IU cholecalciferol (12 drops daily Vitamin D3 Forte Renapharma 20 000 IU/ mL), or matching placebo provided by Merck KGaA. The dose was selected to be close to 50 000 IU/week, which was used in a study where 25(OH) D sufficiency was reached, however, without significant effect on PTH. We aimed for a substantial increase in 25(OH) D, well above 75 nmol/L in all treated subjects, to fully examine the effects on mineral metabolism and also possible pleitropic effects on fatigue and muscle function.

Cholecalciferol and placebo were manufactured in identical vials by the manufacturer. Each vial had a batch number and each subject an identification number based on site and order of inclusion in the study. A statistician employed by the sponsor performed block randomization, which was blinded to all in the staff performing the study. A study nurse provided each participant with the numbered vials allocated to them on the first visit after inclusion in the study.

Participants were seen as outpatients at respective clinics at baseline, after 6 weeks and after 12 weeks. Physical examination, medical history and concomitant medication were registered at baseline, after 6 weeks and after 12 weeks. Physical examination, medical history and concomitant medication were registered at baseline, after 6 weeks and after 12 weeks. Participants were seen as outpatients at respective clinics at baseline, after 6 weeks and after 12 weeks. Physical examination, medical history and concomitant medication were registered at baseline, and any changes in medication or adverse events (AEs) were registered at each visit. After an overnight fast, blood was drawn and centrifuged and serum was stored in 

Biochemical analyses

Biochemical analysis for the screening procedure was done at each hospital. iPTH was analysed with standardized automated immunoassay (Cobas E, Roche). The 25(OH)D was analysed with a chemiluminescent method (Diasorin) in Uppsala, while high-performance liquid chromatography mass spectrometry (HPLC-MS) was used in Malmö and Gothenburg for screening. In the study, the HPLC-MS was used for all further analysis of 25(OH)D. The 1,25(OH)D was analysed using an immunological method (IDS-iSYS 1.25vitD³P, Boldon), and intact fibroblast growth factor 23 (FGF23) with an enzyme-linked immunosorbent assay (Kainos, Japan). Ionized calcium, calcium, phosphate, creatinine in serum and urinary phosphate, creatinine and albumin were analysed using standardized clinical laboratory methods. Fractional excretion (FE) of phosphate was calculated $\frac{\text{[urine phosphate (mmol/L) x serum creatinine (mmol/L)]}}{\text{[urine creatinine (mmol/L) x serum phosphate (mmol/L)]}}$.

Statistical analyses

Values are given as means ± standard deviation (SD), median, range and interquartile range or proportions.

The primary statistical hypothesis to be tested was a difference in mean change in PTH after 12 weeks between groups. This was tested using analysis of covariance (ANCOVA), with baseline PTH as covariate in the model and treatment as a fixed factor. Analysis was done on the full analysis set (FAS) population. The mean change in the secondary endpoint continuous variables was evaluated using the same approach. Categorical variables were evaluated using the chi-square test. Predefined subgroup analyses of participants with CKD Stage 3 or 4 were done. Moreover, subgroups of high or low baseline 25(OH)D levels were analysed where the border was data driven and defined as above or below 57 nmol/L. All statistical analyses were performed using SAS (version 9.3), and all tests were two-sided using the significance level of $P < 0.05$.

Sample size calculation for the primary endpoint was based on our own observational data [9] and a published pilot study...
These data were used to calculate a hypothetical mean and SD of PTH. The PTH values were logarithmically transformed due to skewed distribution. To detect a 30% difference between groups after 12 weeks with a statistical power of 80% and \( P < 0.05 \), 45 patients were estimated to be required per treatment group. With an expected withdrawal rate of 10%, a total sample size of 100 patients was targeted.

RESULTS

Enrolment

The inclusion and randomization took place between 12 March 2012 and 14 March 2014. Following screening a total of 99 patients signed informed consent for participation in the trial. A total of 97 patients (48 in the cholecalciferol and 49 in the placebo group) continued the study after randomization. The FAS population was the primary analysis population and was defined for all patients who took at least one dose of the study drug and had at least one baseline and one post-baseline measure of the primary efficacy variable. The FAS population consisted of 95 subjects, 47 in the cholecalciferol group and 48 in the placebo. During the study, five subjects were withdrawn: two in the cholecalciferol group and three in the placebo group (Figure 1).

Characteristics

Baseline serum concentrations of 25(OH)D, PTH and renal diagnoses are presented in Table 1. The proportion of males was higher in the placebo group: 80% as compared with 56% in the cholecalciferol group (\( P = 0.013 \)). Otherwise the groups were comparable, with a baseline 25(OH)D of 57.5 ± 22 and 56.8 ± 22 nmol/L and a PTH on 10.9 ± 5 and 13.1 ± 9 pmol/L in the cholecalciferol and placebo groups, respectively.

Primary endpoint

The results at baseline and after 12 weeks are presented in Table 2. In the cholecalciferol-treated group, the mean change of PTH was \(-0.7 ± 3\) pmol/L, whereas in the placebo group the mean change in PTH was \(1.6 ± 5\) pmol/L. The difference in mean change between groups was significant when analysed by ANCOVA (\( P = 0.0048 \)).

Secondary and other endpoints

After 6 weeks there was a difference in mean change in PTH between groups (\( P = 0.036 \)). There was no significant difference in the proportion of subjects reaching a 30% decrease in PTH at 6 weeks (14.9 versus 6.3%, \( P = 0.32 \)) or 12 weeks (10.6 versus 4.2%, \( P = 0.27 \)). Eight patients in the treatment group experienced an iPTH level \(<6.8\) pmol/L. Seven of these patients were in CKD Stage 3.

The serum concentration of 25(OH)D increased from 57.5 ± 22 to 161.6 ± 49 nmol/L after 12 weeks in the treatment group but remained unchanged in the placebo group. All subjects in the treatment arm were 25(OH)D sufficient (>75 nmol/L) after 12 weeks (Figure 2).

The 1,25(OH)D increased from 64.5 ± 43 to 101.5 ± 54 pmol/L in the cholecalciferol group.

The calcium concentration remained constant on 2.2 mmol/L in the cholecalciferol group, but decreased from 2.3 ± 0.12 to 2.2 ± 0.13 mmol/L in the placebo group. The difference in mean change was significant (\( P < 0.01 \)).

There were no differences in mean change between the groups in FGF23 or FE of phosphate.

Additionally, there were no differences at 12 weeks between groups in fatigue scores: for physical fatigue score (\( P = 0.11 \)), for mental fatigue score (\( P = 0.25 \)), and for the visual analogue scale (\( P = 0.96 \)) or hand grip strength (\( P = 0.98 \)).

Subgroup analysis

A subgroup analysis was performed to investigate the effect of CKD stage on outcome. In the CKD Stage 3 subgroup, PTH did not change in either treatment group. In the cholecalciferol group, it was 8.6 ± 2.0 pmol/L at baseline and 9.1 ± 3.9 pmol/L after 12 weeks. The corresponding values in the placebo group were 8.8 ± 3.0 at baseline and 8.7 ± 3.3 after 12 weeks. There were no differences in mean change between groups (\( P = 0.95 \)). In CKD Stage 4, the mean PTH changed from 12.5 ± 6.6 to 11.5 ± 5.8 pmol/L in the treatment group, and from 16.4 ± 11.0 to 19.1 ± 12.4 pmol/L in the placebo group. The mean (confidence interval) difference in change between groups was \(-3.8 (−6.5; −1.1) (P = 0.006)\).

Of the subjects, 50% had baseline 25(OH)D <57 nmol/L. They had a significant difference in mean change in PTH between treatment groups –3.15 (−6.0; −0.3) (\( P = 0.03 \)), whereas in the subgroup with 25(OH)D >57 nmol/L it was −1.5 (−3.2; 0.2) (\( P = 0.09 \)).

When further analysed, we found a correlation between 25(OH)D level and iPTH in the treatment group, indicating that even when vitamin D is sufficient it is possible to suppress iPTH with native vitamin D. The linear correlation line could be expressed as \[\text{iPTH (pmol/L)} = 17.05 - 0.00407 \times 25(\text{OH})D (\text{nmol/L})\], theoretically implicating that a mean iPTH of 12 pmol/L corresponds to 25(OH)D of 120 nmol/L and a ‘normal’ level <6.9 pmol/L correlates with 25(OH)D of ~250 nmol/L.
Safety

No deaths were recorded during the course of the trial. In total, 56 AEs were registered during the study, most of which were reported as mild and due to infections or musculoskeletal complaints. None was judged to be related to the study medication. No event of hypercalcaemia defined as ionized calcium above 1.35 mmol/L was recorded. There were no differences in mean change in eGFR between groups. eGFR estimated from cystatin C decreased 0.65 mL/min/1.73 m² in the cholecalciferol group and 1.06 mL/min/1.73 m² in the placebo group (P = 0.086).

Five serious AEs, which required hospitalization for at least 1 day, occurred. In the treatment arm there were 34 AEs, of which three were serious. An 81-year-old male was diagnosed with a 3-mm calculus causing moderate hydronephrosis and temporary worsening of renal function. On re-examination of a computer tomography scan from 4 years earlier, the calculus was seen and the event was classified as unrelated to the study drug. The two other serious AEs in the treatment arm were a pulmonary embolism and one respiratory tract infection. In the placebo arm there were 22 AEs, of which two were serious: one case of haematochezia (due to colonic polyp) and one iron deficiency anaemia of unknown cause.

Table 1. Characteristics of patients randomly selected to cholecalciferol or placebo treatment

| Characteristics          | Cholecalciferol (n = 47) | Placebo (n = 48) | P  |
|--------------------------|--------------------------|-----------------|----|
| Age (years) (mean ± SD)  | 62.6 ± 15                | 64.0 ± 14       | 0.62|
| Males, n (%)             | 26 (56)                  | 38 (80)         | 0.013|
| Females, n (%)           | 21 (44)                  | 10 (20)         |    |
| Weight (kg)              | 83.5 ± 18                | 91.1 ± 22       | 0.06|
| Body mass index (kg/m²)  | 28.4 ± 5                 | 29.3 ± 6        | 0.41|
| eGFR (mL/min/1.73 m²)    | 32.0 ± 13                | 29.5 ± 13       | 0.29|
| CKD Stage 3              | 28 (60)                  | 21 (43)         | 0.13|
| CKD Stage 4              | 19 (40)                  | 27 (57)         | 0.09|
| 25(OH)D (nmol/L)         | 57.5 ± 22                | 56.8 ± 22       | 0.94|
| Intact PTH (pmol/L)      | 10.9 ± 5                 | 13.1 ± 9        | 0.09|
| Renal diagnosis, n (%)   |                          |                 | 0.41|
| Diabetes                 | 16 (34)                  | 15 (31)         |    |
| Glomerulonephritis       | 10 (21)                  | 9 (19)          |    |
| Renovascular disease     | 14 (30)                  | 13 (27)         |    |
| Polycystic kidney disease| 3 (6)                    | 8 (17)          |    |
| Other                    | 4 (9)                    | 3 (6)           |    |

Table 2. Means ± SD for different variables before and after 12 weeks on treatment with cholecalciferol or placebo

|                      | Cholecalciferol | Placebo | P   |
|----------------------|-----------------|---------|-----|
| 25(OH)D (nmol/L)     | 57.5 ± 22       | 61.5 ± 24 | <0.001 |
| iPTH (pmol/L)        | 10.9 ± 5        | 13.1 ± 9   | 0.0048 |
| Calcium (mmol/L)     | 2.2 ± 0.14      | 2.2 ± 0.13 | <0.001 |
| Phosphate (mmol/L)   | 1.2 ± 0.28      | 1.2 ± 0.27 | 0.22 |
| 1,25(OH)D (pmol/L)   | 64 ± 43         | 64 ± 40   | <0.001 |
| FGF23 (pg/mL)        | 132 ± 115       | 138 ± 87  | 0.76 |
| Urinary phosphate (mmol/L) | 14.7 ± 9.6 | 16.3 ± 7.8  | 0.48 |
| Hand grip strength (kg)       | 26.5 ± 11      | 33.2 ± 13  | 0.98 |
| Fatigue score, total (kg)  | 14.7 ± 5       | 13.7 ± 4   | 0.10 |
| Physical             | 9.6 ± 4         | 9 ± 3     | 0.11 |
| Mental               | 5 ± 2           | 4.7 ± 2   | 0.25 |
| VAS (mm)             | 42.6 ± 26       | 38.8 ± 25  | 0.96 |

Data are presented as mean ± SD. P denotes difference in mean change between groups based on ANCOVA with baseline value as covariate. VAS, visual analogue scale.

FIGURE 2: Individual observations of 25(OH)D before and after 12 weeks on cholecalciferol treatment.
DISCUSSION

In this double-blind, randomized, placebo-controlled clinical study in CKD Stages 3 and 4 patients with SHPT, we showed that a daily high dose of oral cholecalciferol alleviates a further increase in PTH. We also demonstrate that all cholecalciferol-treated subjects become 25(OH)D sufficient after 3 months. Despite a substantial increase in 25(OH)D and 1,25(OH)D there were no cases of hypercalcaemia in the treatment group. Furthermore, no differences in changes in FGF23 or urinary phosphate excretion between the groups were observed. On the other hand, we saw no effect on the patient-pertinent symptoms fatigue or hand grip strength.

At least to our knowledge, this is the first sufficiently powered study of high-dose cholecalciferol in CKD to show an effect on SHPT. Earlier studies have consistently demonstrated a dose-related increase in 25(OH)D and a trend to lower PTH.

Chandra et al. [10] performed a randomized study of 50 000 IU cholecalciferol weekly (n = 10) versus placebo (n = 10) in CKD Stages 3 and 4 subjects and reached 25(OH)D sufficiency: median (range) 124 (85–180) nmol/L, while median PTH decreased from 30 to 21 pmol/L, but there were no differences in PTH change compared with the placebo group (P = 0.14).

Rucker et al. [11] treated 128 CKD Stages 3–5 patients, not on dialysis, with 1000 IU cholecalciferol daily or placebo for 12 weeks, and found that 25(OH)D increased significantly. Though >50% of treated subjects reached a 25(OH)D exceeding 75 nmol/L after 12 weeks, there were no differences in PTH between groups.

Moe et al. [12] compared cholecalciferol 4000 IU daily for 1 month followed by 2000 IU daily for 2 months (n = 22) with doxercalciferol (n = 25) in a randomized controlled trial for 12 weeks in CKD Stages 3 and 4. The mean 25(OH)D increased from 35 ± 15 to 92.5 ± 25 nmol/L (P < 0.001) in the cholecalciferol group, and mean PTH decreased with 10% from 11.5 ± 4.6 to 10.3 ± 5.2 pmol/L (P = 0.15). The PTH decreased by 30% in the doxercalciferol group but there was no significant difference in mean change between groups (P = 0.19). There was no increase in serum calcium or urinary calcium/creatinine in the cholecalciferol group. In contrast to our results, where we observed a significant change in PTH levels in CKD Stage 4 patients and no difference in CKD Stage 3, their subgroup analysis showed that the PTH reduction was in CKD Stage 3, whereas there were no effects in CKD Stage 4.

Zisman et al. [13] performed an open non-randomized study on 52 CKD Stages 3 and 4 patients with ergocalciferol according to K/DOQI guidelines recommendations. The effect on 25(OH)D was similar in CKD Stages 3 and 4 subjects, reaching mean levels of 78.8 ± 5.5 and 88.4 ± 4.2 nmol/L, respectively. They observed a median decrease in PTH of 13% (P = 0.04) in CKD Stage 3 but no effect in CKD Stage 4.

In our study, we used a higher cholecalciferol dose and aimed for higher 25(OH)D concentrations. The PTH reduction in the treatment arm was 6.4% and the increase in the placebo arm was 12.2%. In contrast to earlier studies, the effect was non-significant in the CKD Stage 3 subgroup, whereas it was significant only in CKD Stage 4 due to the larger increase in PTH in placebo-treated patients.

Alvarez et al. [14] performed a 1-year clinical trial of high-dose cholecalciferol. They included 46 CKD Stages 2 and 3 patients who were randomized to cholecalciferol 50 000 IU weekly for 12 weeks followed by 50 000 IU every other week for 40 weeks or matching placebo. The 25(OH)D sufficiency was reached and maintained in the cholecalciferol group, and there was a significant decrease in PTH after 12 weeks (P = 0.01), whereas there were no differences between groups after 52 weeks (P = 0.16). Like in our study, the effect of cholecalciferol on PTH was driven by participants with higher PTH and worse renal function.

Shroff et al. [15] showed in children with CKD that treatment with ergocalciferol can postpone the development of SHPT. Likewise in that study, we showed that cholecalciferol counteracts the development of SHPT in CKD. To reach an effect, especially as eGFR decreases below 30 mL/min/1.73 m² it seems necessary to use a dose that increases the 25(OH)D concentration above 75 nmol/L.

In the treatment arm there was a marked increase in 1,25(OH)D, but ionized calcium remained constant and there were no observations of hypercalcaemia. The FE-Pi is the fraction of filtered phosphate that is actually excreted in the urine. It increases as renal function declines to counteract hyperphosphataemia. Both PTH and FGF23 down-regulate the sodium–phosphate cotransporters NaPi2a and 2c in the renal tubules. PTH and FGF23 are highly and independently correlated in cross-sectional studies. Higher 1,25(OH)D is expected to increase FGF23, but we did not detect any difference in change in FGF23 between groups.

Fatigue is a common symptom in CKD, and vitamin D deficiency has been proposed as a treatable cause of fatigue in different patient groups. Using a validated questionnaire of self-estimated fatigue we could not detect any effect of high-dose cholecalciferol on fatigue in our study.

Musculoskeletal function may be impaired in situations with vitamin D deficiency. It has mostly been described as proximal muscle weakness in the elderly. However, we could not detect any effect on peripheral muscle strength measured as hand grip strength in the present study.

The dosing of cholecalciferol drops 8000 IU daily for 12 weeks seems safe and well tolerated in CKD patients with a 25(OH)D level that could be expected in most CKD patients not receiving vitamin D supplementation. There were no cases of significant hypercalcaemia, and mean difference in eGFR showed no difference between groups. The AEs were judged to be unrelated to the treatment even in the case with ureteral obstruction due to a known calculus.

The strengths of this study are that it was carefully performed as a randomized double-blind placebo-controlled clinical study with adequate power on representative CKD patients. We analysed several parameters of mineral metabolism, such as 1,25(OH)D and FGF23, which may help in mechanistically interpreting the dynamics of renal SHPT.

The limitations are that it is only a 3-month study of a disease process that develops and continues during years and
...the development of SHPT as it attains complete 25(OH)D sufficiency and induces an substantial increase in 1,25(OH)D, thereby avoiding the tendency to hypocalcaemia that otherwise develops. High-dose cholecalciferol (8000 IU/day) does not cause hypercalcemia or accelerated loss of GFR. Furthermore, high-dose cholecalciferol (8000 IU/day) does not induce an increase in phosphate or FGF23, yet, on the other hand, does not improve fatigue or hand grip strength.

Our data support the guidelines that 25(OH)D insufficiency should be addressed before calcium-based phosphate binders or active vitamin D analogues are introduced in CKD patients with SHPT. We also suggest that the 25(OH)D sufficiency should be reached early in CKD and maintained, to slow the development of SHPT.

**FUNDING**

This study was supported by the Uppsala University Hospital. Renapharma AB was the sponsor of the study and provided study medication, monitoring and financial support for laboratory analyses.

**ACKNOWLEDGEMENTS**

We thank the following for their assistance in this study: Åsa Lidman, research nurse, Uppsala University Hospital; Ewa Johnsson, research nurse, Skåne University Hospital; and Malmö, Lotta Sundström and Maria Just, research nurses, Sahlgrenska University Hospital, Gothenburg; in addition, biostatistician Catarina Jansson Blixt, Scandinavian CRO, and MSc Study Monitor Lennart Jönsson, research nurse.

**CONFLICT OF INTEREST STATEMENT**

This study was investigator-initiated and sponsored by Renapharma AB, Sweden, which provided the study medication and monitored the study.

**REFERENCES**

1. Chapuy MC, Preziosi P, Maamer M et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439–443
2. Bischoff-Ferrari HA, Giovannucci E, Willett WC et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18–28
3. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777–783
4. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3): S1–S201
5. K/DOQI clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1–S130
6. Holick MF. Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 2010; 39: 381–400
7. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–281
8. Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–153
9. Westerberg PA, Linde T, Wikstrom B et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202–3207
10. Chandra P, Binongo JN, Ziegler TR et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14: 10–17
11. Rucker D, Tonelli M, Coles MG et al. Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 2009; 22: 75–82
12. Moe SM, Safiullah A, LaClair RE et al. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 299–306
13. Zisman AL, Hristova M, Ho LT et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27: 36–43
14. Alvarez JA, Law J, Coaldey KE et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672–679
15. Shroff R, Wan M, Gallett A et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012; 7: 216–223

Received: 3.11.2016; Editorial decision: 4.3.2017